Study identifier:SH-SBC-0012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase I study to investigate the safety and pharmacokinetics of AZ242 after repeated oral dosing (3 mg once daily) in healthy male Japanese subjects (single-blind, rondomized, placebo-controlled, parallel group study)
Diabetes Mellitus
Phase 1
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
-
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|